Interaction of TGF-β with immune cells in airway disease

Benjamin Moore, Richard F. Murphy, Devendra K. Agrawal

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Asthma, chronic obstructive pulmonary disorder (COPD), and cystic fibrosis (CF), chronic diseases of the airways, are characterized by symptoms such as inflammation of the lung tissue, mucus hypersecretion, constriction of the airways, and excessive fibrosis of airway tissue. Transforming growth factor (TGF)-β, a cytokine that affects many different cell processes, has an important role in the lungs of patients with some of these chronic airway diseases, especially with respect to airway remodeling. Eosinophils can be activated by and are a major source of TGF-β in asthma. The action of TGF-β also shows associations with other cell types, such as T cells and neutrophils, which are involved in the pathogenesis of asthma. TGF-β can perpetuate the pathogenesis of COPD and CF, as well, through its induction of inflammation via release from and action on different cells. The intracellular signaling induced by TGF-β in various cell types has been elucidated and may point to mechanisms of action by TGF-β on different structural or immune cells in these airway diseases. Some possible treatments, especially that prevent the deleterious airway changes induced by the action of either eosinophils or TGF-β in asthma, have been investigated. TGF-β-induced signaling pathways, especially those in different cell types in asthma, COPD, or CF, may provide potential therapeutic targets for the treatment of some of the most devastating airway diseases.

Original languageEnglish
Pages (from-to)427-436
Number of pages10
JournalCurrent Molecular Medicine
Volume8
Issue number5
DOIs
StatePublished - Aug 2008

Fingerprint

Transforming Growth Factors
Asthma
Cystic Fibrosis
Eosinophils
Chronic Disease
Tissue
Airway Remodeling
T-cells
Pulmonary Fibrosis
Mucus
Constriction
Pneumonia
Neutrophils
Fibrosis
Therapeutics
Cytokines
Inflammation
T-Lymphocytes
Lung

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Interaction of TGF-β with immune cells in airway disease. / Moore, Benjamin; Murphy, Richard F.; Agrawal, Devendra K.

In: Current Molecular Medicine, Vol. 8, No. 5, 08.2008, p. 427-436.

Research output: Contribution to journalReview article

Moore, Benjamin ; Murphy, Richard F. ; Agrawal, Devendra K. / Interaction of TGF-β with immune cells in airway disease. In: Current Molecular Medicine. 2008 ; Vol. 8, No. 5. pp. 427-436.
@article{e8f57a7ba94b49039d002a5c5458bfec,
title = "Interaction of TGF-β with immune cells in airway disease",
abstract = "Asthma, chronic obstructive pulmonary disorder (COPD), and cystic fibrosis (CF), chronic diseases of the airways, are characterized by symptoms such as inflammation of the lung tissue, mucus hypersecretion, constriction of the airways, and excessive fibrosis of airway tissue. Transforming growth factor (TGF)-β, a cytokine that affects many different cell processes, has an important role in the lungs of patients with some of these chronic airway diseases, especially with respect to airway remodeling. Eosinophils can be activated by and are a major source of TGF-β in asthma. The action of TGF-β also shows associations with other cell types, such as T cells and neutrophils, which are involved in the pathogenesis of asthma. TGF-β can perpetuate the pathogenesis of COPD and CF, as well, through its induction of inflammation via release from and action on different cells. The intracellular signaling induced by TGF-β in various cell types has been elucidated and may point to mechanisms of action by TGF-β on different structural or immune cells in these airway diseases. Some possible treatments, especially that prevent the deleterious airway changes induced by the action of either eosinophils or TGF-β in asthma, have been investigated. TGF-β-induced signaling pathways, especially those in different cell types in asthma, COPD, or CF, may provide potential therapeutic targets for the treatment of some of the most devastating airway diseases.",
author = "Benjamin Moore and Murphy, {Richard F.} and Agrawal, {Devendra K.}",
year = "2008",
month = "8",
doi = "10.2174/156652408785160943",
language = "English",
volume = "8",
pages = "427--436",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Interaction of TGF-β with immune cells in airway disease

AU - Moore, Benjamin

AU - Murphy, Richard F.

AU - Agrawal, Devendra K.

PY - 2008/8

Y1 - 2008/8

N2 - Asthma, chronic obstructive pulmonary disorder (COPD), and cystic fibrosis (CF), chronic diseases of the airways, are characterized by symptoms such as inflammation of the lung tissue, mucus hypersecretion, constriction of the airways, and excessive fibrosis of airway tissue. Transforming growth factor (TGF)-β, a cytokine that affects many different cell processes, has an important role in the lungs of patients with some of these chronic airway diseases, especially with respect to airway remodeling. Eosinophils can be activated by and are a major source of TGF-β in asthma. The action of TGF-β also shows associations with other cell types, such as T cells and neutrophils, which are involved in the pathogenesis of asthma. TGF-β can perpetuate the pathogenesis of COPD and CF, as well, through its induction of inflammation via release from and action on different cells. The intracellular signaling induced by TGF-β in various cell types has been elucidated and may point to mechanisms of action by TGF-β on different structural or immune cells in these airway diseases. Some possible treatments, especially that prevent the deleterious airway changes induced by the action of either eosinophils or TGF-β in asthma, have been investigated. TGF-β-induced signaling pathways, especially those in different cell types in asthma, COPD, or CF, may provide potential therapeutic targets for the treatment of some of the most devastating airway diseases.

AB - Asthma, chronic obstructive pulmonary disorder (COPD), and cystic fibrosis (CF), chronic diseases of the airways, are characterized by symptoms such as inflammation of the lung tissue, mucus hypersecretion, constriction of the airways, and excessive fibrosis of airway tissue. Transforming growth factor (TGF)-β, a cytokine that affects many different cell processes, has an important role in the lungs of patients with some of these chronic airway diseases, especially with respect to airway remodeling. Eosinophils can be activated by and are a major source of TGF-β in asthma. The action of TGF-β also shows associations with other cell types, such as T cells and neutrophils, which are involved in the pathogenesis of asthma. TGF-β can perpetuate the pathogenesis of COPD and CF, as well, through its induction of inflammation via release from and action on different cells. The intracellular signaling induced by TGF-β in various cell types has been elucidated and may point to mechanisms of action by TGF-β on different structural or immune cells in these airway diseases. Some possible treatments, especially that prevent the deleterious airway changes induced by the action of either eosinophils or TGF-β in asthma, have been investigated. TGF-β-induced signaling pathways, especially those in different cell types in asthma, COPD, or CF, may provide potential therapeutic targets for the treatment of some of the most devastating airway diseases.

UR - http://www.scopus.com/inward/record.url?scp=53849126120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849126120&partnerID=8YFLogxK

U2 - 10.2174/156652408785160943

DO - 10.2174/156652408785160943

M3 - Review article

VL - 8

SP - 427

EP - 436

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 5

ER -